Sanjay’s education and biomedical research training have provided him a broad scientific foundation needed for the proposed research. He completed his PhD at the National Institute of Virology, Pune (INDIA), focusing on the function of T regulatory cells in hepatitis E virus infection. As a graduate student, he published four first and three co-author publications. After his PhD he worked in a private organization developing inhibitors for immune-checkpoint and ROR-γt for treatment of cancer/autoimmune diseases. His leadership roles included teaching and mentoring students.
He joined Dr. Christian Fernandez at Department of Pharmaceutical Sciences as a postdoctoral research associate in December 2016. His projects involve improving the treatment of pediatric ALL by limiting adverse drug reactions and attaining therapeutic drug exposures. Currently, Sanjay mainly focuses on asparaginase (ASNase), which is among the main drugs used for the treatment of pediatric ALL. Immune responses to ASNase are the most common toxicity of the drug, and, moreover, patients that develop anti-ASNase antibodies during treatment have a higher risk of CNS relapse. Therefore, he is identifying the mechanism of hypersensitivity and methods to extend ASNase exposure after an immune response hopefully reducing the risk of relapse among these patients.
He is also interested in simultaneously monitoring anti-adalimumab (anti-ADA) IgG levels and plasma adalimumab (ADA) concentrations to determine the frequency of anti-ADA antibodies among patients enrolled in the Rheumatoid Arthritis Comparative and Effectiveness Research (RACER) study at UPMC, Pittsburgh.